MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CG Oncology, Inc. - Common stock (NQ:CGON)

74.44 +0.71 (+0.96%)
Streaming Delayed Price Updated: 10:08 AM EDT, Jun 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 181,928
Open 75.07
Bid (Size) 74.30 (100)
Ask (Size) 74.47 (100)
Prev. Close 73.73
Today's Range 73.00 - 77.00
52wk Range 23.65 - 75.50
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead ↗
CG Oncology (NASDAQ:CGON) Chief Executive Officer Arthur outlined the company’s upcoming clinical and regulatory milestones for cretostimogene during a presentation at the Goldman Sachs Global... 
Via MarketBeat
Topics Initial Public Offering
News headline image
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push ↗
CG Oncology (NASDAQ:CGON) is focused on advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, Chief Executive Officer Arthur Kuan said during a discussion at the... 
Via MarketBeat
Topics Initial Public Offering

Performance

YTD
+78.1%
+78.1%
1 Month
+25.7%
+25.7%
3 Month
+16.4%
+16.4%
6 Month
+86.8%
+86.8%
1 Year
+186.3%
+186.3%

More News

Read More
News headline image
CG Oncology to Present at Upcoming Investor Conferences in June
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference ↗
Via MarketBeat
Topics Initial Public Offering
CG Oncology Inc (NASDAQ:CGON) Shows Perfect Technical Rating and Strong Setup Quality for Potential Breakout ↗
Via Chartmill
News headline image
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears ↗
Via MarketBeat
Topics Initial Public Offering
News headline image
CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings ↗
Via Benzinga
News headline image
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology to Present at Upcoming Investor Conferences in May
From CG Oncology Inc.
Via GlobeNewswire
News headline image
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗
Via The Motley Fool
News headline image
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth
Via MarketMinute
Topics Earnings Economy
News headline image
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
Via MarketMinute
Topics Intellectual Property
What's going on in today's session ↗
Via Chartmill
Keep an eye on the top gainers and losers in Friday's session. ↗
Via Chartmill
News headline image
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
From CG Oncology Inc.
Via GlobeNewswire
News headline image
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗
Via The Motley Fool
News headline image
SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
From CG Oncology Inc.
Via GlobeNewswire

Frequently Asked Questions

Is CG Oncology, Inc. - Common stock publicly traded?
Yes, CG Oncology, Inc. - Common stock is publicly traded.
What exchange does CG Oncology, Inc. - Common stock trade on?
CG Oncology, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for CG Oncology, Inc. - Common stock?
The ticker symbol for CG Oncology, Inc. - Common stock is CGON on the Nasdaq Stock Market
What is the current price of CG Oncology, Inc. - Common stock?
The current price of CG Oncology, Inc. - Common stock is 74.44
When was CG Oncology, Inc. - Common stock last traded?
The last trade of CG Oncology, Inc. - Common stock was at 06/30/26 10:08 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story